PDGFRB and breast cancer: We examined locally advanced non-metastatic renal tumors treated with the PDGFR/VEGFR inhibitor sunitinib, metastatic breast cancers treated with docetaxel in combination with sunitinib, and metastatic ER+ breast tumors treated with tamoxifen in combination with the PDGF/VEGFR/Ras/Raf/MAPK inhibitor sorafenib (Figure S5H).